Exelixis, Inc., a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. It also offers COTELLIC tablets, an inhibitor of MEK in combination with vemurafenib for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma in the United States; and in combination with vemurafenib in other territories, including the European Union, Switzerland, Canada, Australia, and Brazil. Exelixis, Inc. has collaboration and license agreement with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, Daiichi Sankyo Company Limited, and Invenra, Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Commercial physical research
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:EXEL
Previous Symbol
CUSIP30161Q10
Phone650-837-7000
Debt
Debt-to-Equity Ratio0.01
Current Ratio8.66
Quick Ratio8.54
Price-To-Earnings
Trailing P/E Ratio41.24
Forward P/E Ratio16.18
P/E Growth1.25
Sales & Book Value
Annual Sales$452.48 million
Price / Sales13.90
Cash Flow$0.5469 per share
Price / Cash Flow38.45
Book Value$0.96 per share
Price / Book21.91
Profitability
EPS (Most Recent Fiscal Year)$0.51
Net Income$154.22 million
Net Margins49.53%
Return on Equity55.71%
Return on Assets43.79%
Miscellaneous
Employees372
Outstanding Shares298,980,000
Market Cap$6.29 billion
OptionableOptionable
Exelixis (NASDAQ:EXEL) Frequently Asked Questions
What is Exelixis' stock symbol?
Exelixis trades on the NASDAQ under the ticker symbol "EXEL."
How were Exelixis' earnings last quarter?
Exelixis, Inc. (NASDAQ:EXEL) posted its quarterly earnings data on Thursday, November, 1st. The biotechnology company reported $0.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.19 by $0.22. The biotechnology company had revenue of $225.40 million for the quarter, compared to analysts' expectations of $174.14 million. Exelixis had a return on equity of 55.71% and a net margin of 49.53%. The business's revenue was up 47.8% on a year-over-year basis. During the same quarter last year, the firm earned $0.26 earnings per share. View Exelixis' Earnings History.
When is Exelixis' next earnings date?
What price target have analysts set for EXEL?
10 brokerages have issued twelve-month price targets for Exelixis' stock. Their predictions range from $19.00 to $40.00. On average, they anticipate Exelixis' share price to reach $28.5714 in the next twelve months. This suggests a possible upside of 35.9% from the stock's current price. View Analyst Price Targets for Exelixis.
What is the consensus analysts' recommendation for Exelixis?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exelixis in the last year. There are currently 1 sell rating, 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Exelixis.
Has Exelixis been receiving favorable news coverage?
News coverage about EXEL stock has trended somewhat positive on Sunday, InfoTrie Sentiment reports. The research group ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Exelixis earned a news impact score of 1.0 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Are investors shorting Exelixis?
Exelixis saw a drop in short interest during the month of November. As of November 30th, there was short interest totalling 11,316,263 shares, a drop of 29.1% from the November 15th total of 15,962,061 shares. Based on an average daily trading volume, of 3,751,958 shares, the short-interest ratio is presently 3.0 days. Currently, 3.9% of the company's shares are short sold. View Exelixis' Current Options Chain.
Who are some of Exelixis' key competitors?
Some companies that are related to Exelixis include Iqvia (IQV), Incyte (INCY), EXACT Sciences (EXAS), Icon (ICLR), PRA Health Sciences (PRAH), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), BTG (BTGGF), Medpace (MEDP), Sorrento Therapeutics (SRNE), Pieris Pharmaceuticals (PIRS), Anavex Life Sciences (AVXL), Luna Innovations (LUNA), Senomyx (SNMX) and HedgePath Pharmaceuticals (HPPI).
Who are Exelixis' key executives?
Exelixis' management team includes the folowing people:
- Dr. Stelios Papadopoulos, Co-Founder & Chairman (Age 70)
- Dr. Michael M. Morrissey, CEO, Pres & Director (Age 57)
- Mr. Christopher J. Senner, Exec. VP & CFO (Age 50)
- Dr. Peter Lamb, Exec. VP of Scientific Strategy & Chief Scientific Officer (Age 57)
- Mr. Jeffrey J. Hessekiel, Exec. VP, Gen. Counsel & Sec. (Age 49)
Who are Exelixis' major shareholders?
Exelixis' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (10.07%), Vanguard Group Inc. (8.87%), Vanguard Group Inc (8.87%), FMR LLC (8.24%), JPMorgan Chase & Co. (1.98%) and MERIAN GLOBAL INVESTORS UK Ltd (1.57%). Company insiders that own Exelixis stock include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jack L Wyszomierski, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi. View Institutional Ownership Trends for Exelixis.
Which institutional investors are selling Exelixis stock?
EXEL stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Wells Fargo & Company MN, Macquarie Group Ltd., Deutsche Bank AG, AQR Capital Management LLC, Marshall Wace North America L.P., Allianz Asset Management GmbH and Handelsbanken Fonder AB. Company insiders that have sold Exelixis company stock in the last year include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Stelios Papadopoulos and Vincent T Marchesi. View Insider Buying and Selling for Exelixis.
Which institutional investors are buying Exelixis stock?
EXEL stock was bought by a variety of institutional investors in the last quarter, including First Trust Advisors LP, BB Biotech AG, BlackRock Inc., MERIAN GLOBAL INVESTORS UK Ltd, Marshall Wace LLP, Vanguard Group Inc, Vanguard Group Inc. and American International Group Inc.. View Insider Buying and Selling for Exelixis.
How do I buy shares of Exelixis?
Shares of EXEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Exelixis' stock price today?
One share of EXEL stock can currently be purchased for approximately $21.03.
How big of a company is Exelixis?
Exelixis has a market capitalization of $6.29 billion and generates $452.48 million in revenue each year. The biotechnology company earns $154.22 million in net income (profit) each year or $0.51 on an earnings per share basis. Exelixis employs 372 workers across the globe.
What is Exelixis' official website?
How can I contact Exelixis?
Exelixis' mailing address is 1851 Harbor Bay Parkway, Alameda CA, 94502. The biotechnology company can be reached via phone at 650-837-7000 or via email at [email protected]
MarketBeat Community Rating for Exelixis (NASDAQ EXEL)
MarketBeat's community ratings are surveys of what our community members think about Exelixis and other stocks. Vote "Outperform" if you believe EXEL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EXEL will underperform the S&P 500 over the long term. You may vote once every thirty days.
